BN Business News
أضف شركتك →
تجري حاليًا ترجمة هذا المقال. نعرض مؤقتًا النسخة الأصلية باللغة الإنجليزية.

الأعمال · 23‏/12‏/20021 دقائق للقراءة

SoloPak Laboratories, Inc.; Withdrawal of Approval of 1 New Drug Application and 38 Abbreviated New Drug Applications; Correction

ترجمة آلية محلية · اللغة الأصلية للمصدر

الملخص

The Food and Drug Administration (FDA) is correcting a notice that appeared in the Federal Register of June 21, 1999 (64 FR 33097; corrected July 19, 1999 (64 FR 38675)). The document, which announced the withdrawal of approval of 1 new drug application (NDA) and 38 abbeviated new drug applications held by SoloPak Laboratories, Inc., inadvertently withdrew approval of NDA 19-961 for Ganite (gallium nitrate). FDA has subsequently learned that SoloPak, at the time it requested withdrawal of this NDA, was not its holder. Therefore, SoloPak was not authorized to make such a request. FDA confirms that approval of NDA 19-961, currently held by Genta, Inc., is still in effect.

اللغة الأصلية للمصدر: Federal Register — Food and Drug Administrationافتح البيان الأصلي →

استكشف الموضوعات

تحليلات الأعمال →